EF Hutton Reiterates Buy on CalciMedica, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on CalciMedica (NASDAQ:CALC) and maintained a price target of $17.
July 07, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on CalciMedica and maintained a price target of $17.
The reiteration of a 'Buy' rating and maintenance of a $17 price target by EF Hutton analyst Tony Butler indicates a positive outlook for CalciMedica. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100